104 related articles for article (PubMed ID: 23381744)
1. Bone mineral density and risk of breast cancer in postmenopausal women.
Qu X; Zhang X; Qin A; Liu G; Zhai Z; Hao Y; Li H; Zhu Z; Dai K
Breast Cancer Res Treat; 2013 Feb; 138(1):261-71. PubMed ID: 23381744
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies.
Qu X; Huang X; Jin F; Wang H; Hao Y; Tang T; Dai K
Int J Cardiol; 2013 Jun; 166(2):385-93. PubMed ID: 22112679
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density and risk of postmenopausal breast cancer.
Grenier D; Cooke AL; Lix L; Metge C; Lu H; Leslie WD
Breast Cancer Res Treat; 2011 Apr; 126(3):679-86. PubMed ID: 20838879
[TBL] [Abstract][Full Text] [Related]
4. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
5. Independent predictors of all osteoporosis-related fractures among healthy Saudi postmenopausal women: the CEOR Study.
Rouzi AA; Al-Sibiani SA; Al-Senani NS; Radaddi RM; Ardawi MS
Bone; 2012 Mar; 50(3):713-22. PubMed ID: 22178778
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.
Cauley JA; Song J; Dowsett SA; Mershon JL; Cummings SR
Breast Cancer Res Treat; 2007 Apr; 102(2):181-8. PubMed ID: 17028986
[TBL] [Abstract][Full Text] [Related]
8. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.
Trémollieres FA; Pouillès JM; Drewniak N; Laparra J; Ribot CA; Dargent-Molina P
J Bone Miner Res; 2010 May; 25(5):1002-9. PubMed ID: 20200927
[TBL] [Abstract][Full Text] [Related]
10. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
11. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
12. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
13. Disc space narrowing is associated with an increased vertebral fracture risk in postmenopausal women: the OFELY Study.
Sornay-Rendu E; Munoz F; Duboeuf F; Delmas PD;
J Bone Miner Res; 2004 Dec; 19(12):1994-9. PubMed ID: 15537442
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
[TBL] [Abstract][Full Text] [Related]
15. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.
Cummings SR; Cawthon PM; Ensrud KE; Cauley JA; Fink HA; Orwoll ES; ;
J Bone Miner Res; 2006 Oct; 21(10):1550-6. PubMed ID: 16995809
[TBL] [Abstract][Full Text] [Related]
16. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis and fracture risk in women of different ethnic groups.
Barrett-Connor E; Siris ES; Wehren LE; Miller PD; Abbott TA; Berger ML; Santora AC; Sherwood LM
J Bone Miner Res; 2005 Feb; 20(2):185-94. PubMed ID: 15647811
[TBL] [Abstract][Full Text] [Related]
19. Influence of number of pregnancies on bone mineral density in postmenopausal women of different age groups.
Gur A; Nas K; Cevik R; Sarac AJ; Ataoglu S; Karakoc M
J Bone Miner Metab; 2003; 21(4):234-41. PubMed ID: 12811629
[TBL] [Abstract][Full Text] [Related]
20. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
